Baidu
map

JACC子刊:新一代药物洗脱支架PCI后,女性更容易出现胸痛!

2016-03-30 Seven L MedSci原创

合并分析DUTCH PEERS和TWENTE随机试验后发现,使用新一代药物洗脱支架进行PCI的临床相关性胸痛的发生率具有性别差异,女性显著高于男性!合并分析研究共包括3202名稳定性或急性ACS患者,使用新一代永久性聚合物涂层的药物洗脱支架治疗。DUTCH PEERS试验中,患者随机分为Resolute佐他莫司洗脱支架 (Medtronic Vascular)或Xience V依维莫司洗脱支架(A

合并分析DUTCH PEERS和TWENTE随机试验后发现,使用新一代药物洗脱支架进行PCI的临床相关性胸痛的发生率具有性别差异,女性显著高于男性!

合并分析研究共包括3202名稳定性或急性ACS患者,使用新一代永久性聚合物涂层的药物洗脱支架治疗。DUTCH PEERS试验中,患者随机分为Resolute佐他莫司洗脱支架 (Medtronic Vascular)或Xience V依维莫司洗脱支架(Abbott Vascular)。TWENTE试验中,患者随机分为Resolute佐他莫司洗脱支架 (Medtronic Vascular)或Promus Element依维莫司洗脱支架(Boston Scientific)。

合并研究后,27%的患者为女性,与男性相比,女性年龄更大(平均 67.5岁 vs 62.8岁)、更多的CV危险因素:糖尿病(24.2% vs. 17.8%)、高血压(63.6% vs. 51.6%)、相关家族史(54.5% vs. 50.1%)。

研究人员对PCI术后第1年和第2年患者的胸痛情况进行了分析,数据来自于患者门诊或电话/医疗问卷调查随访。其中有99.8%的患者有临床随访数据,术后第1年和第2年胸痛发生率分别为94.1%和93.6%。

PCI术后第1年,患者自我报告的临床相关性胸痛的发生率在女性中更多见(16.3% vs. 10.5%; P < .001),第2年仍是女性患者胸痛情况更多见(17.2% vs. 11.1%; P < .001)。

多因素分析显示,“性别”是随访过程中临床相关性胸痛的独立预测因素。在PCI术后第2年,正常活动时,女性患者的胸痛风险增加1.8倍,休息时为1.7倍。

不过无论男女患者,在第2年,其心肌梗死死亡率、血运重建、支架血栓形成和复合终点的发生率是相似的。

研究者总结说:“虽然使用新一代药物洗脱支架进行PCI后,心血管不良事件发生率在男女患者见不存在差异,但是女性患者却比男性患者有显著更高的胸痛发生率,胸痛的发生可能是不同于冠状动脉阻塞的机制所致。”

原始出处:

Kok MM, et al.Sex Difference in Chest Pain After Implantation of Newer Generation Coronary Drug-Eluting Stents. J Am Coll Cardiol Intv. 2016;doi:10.1016/j.jcin.2015.10.043.

Women undergoing PCI with newer DES have higher prevalence of chest pain.Healio.March 29, 2016

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1998735, encodeId=bf771998e35ca, content=<a href='/topic/show?id=80936510423' target=_blank style='color:#2F92EE;'>#洗脱支架#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65104, encryptionId=80936510423, topicName=洗脱支架)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e72268, createdName=zhixianchen, createdTime=Sun Mar 12 16:57:00 CST 2017, time=2017-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1853508, encodeId=75de18535080f, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Thu Oct 06 02:57:00 CST 2016, time=2016-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1310469, encodeId=f7d3131046998, content=<a href='/topic/show?id=f70e8e78941' target=_blank style='color:#2F92EE;'>#药物洗脱支架#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87789, encryptionId=f70e8e78941, topicName=药物洗脱支架)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Fri Apr 01 08:57:00 CST 2016, time=2016-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325214, encodeId=8fc7132521441, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Fri Apr 01 08:57:00 CST 2016, time=2016-04-01, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1998735, encodeId=bf771998e35ca, content=<a href='/topic/show?id=80936510423' target=_blank style='color:#2F92EE;'>#洗脱支架#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65104, encryptionId=80936510423, topicName=洗脱支架)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e72268, createdName=zhixianchen, createdTime=Sun Mar 12 16:57:00 CST 2017, time=2017-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1853508, encodeId=75de18535080f, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Thu Oct 06 02:57:00 CST 2016, time=2016-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1310469, encodeId=f7d3131046998, content=<a href='/topic/show?id=f70e8e78941' target=_blank style='color:#2F92EE;'>#药物洗脱支架#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87789, encryptionId=f70e8e78941, topicName=药物洗脱支架)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Fri Apr 01 08:57:00 CST 2016, time=2016-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325214, encodeId=8fc7132521441, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Fri Apr 01 08:57:00 CST 2016, time=2016-04-01, status=1, ipAttribution=)]
    2016-10-06 hbwxf
  3. [GetPortalCommentsPageByObjectIdResponse(id=1998735, encodeId=bf771998e35ca, content=<a href='/topic/show?id=80936510423' target=_blank style='color:#2F92EE;'>#洗脱支架#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65104, encryptionId=80936510423, topicName=洗脱支架)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e72268, createdName=zhixianchen, createdTime=Sun Mar 12 16:57:00 CST 2017, time=2017-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1853508, encodeId=75de18535080f, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Thu Oct 06 02:57:00 CST 2016, time=2016-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1310469, encodeId=f7d3131046998, content=<a href='/topic/show?id=f70e8e78941' target=_blank style='color:#2F92EE;'>#药物洗脱支架#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87789, encryptionId=f70e8e78941, topicName=药物洗脱支架)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Fri Apr 01 08:57:00 CST 2016, time=2016-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325214, encodeId=8fc7132521441, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Fri Apr 01 08:57:00 CST 2016, time=2016-04-01, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1998735, encodeId=bf771998e35ca, content=<a href='/topic/show?id=80936510423' target=_blank style='color:#2F92EE;'>#洗脱支架#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65104, encryptionId=80936510423, topicName=洗脱支架)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e72268, createdName=zhixianchen, createdTime=Sun Mar 12 16:57:00 CST 2017, time=2017-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1853508, encodeId=75de18535080f, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Thu Oct 06 02:57:00 CST 2016, time=2016-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1310469, encodeId=f7d3131046998, content=<a href='/topic/show?id=f70e8e78941' target=_blank style='color:#2F92EE;'>#药物洗脱支架#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87789, encryptionId=f70e8e78941, topicName=药物洗脱支架)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Fri Apr 01 08:57:00 CST 2016, time=2016-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325214, encodeId=8fc7132521441, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Fri Apr 01 08:57:00 CST 2016, time=2016-04-01, status=1, ipAttribution=)]

相关资讯

JACC:冠状动脉支架植入1年内,其是心脑血管事件的独立危险因素

以前的研究已经发现接受非心脏手术(NCS)的冠状动脉支架患者围术期心脑血管事件发生率较高。但这一发现是否反映一个独立的关联是不确定的。这项研究的目的是评估之前接受过冠状动脉支架植入术和围手术期主要不良心脏和脑血管事件(MACCE)的发生及出血之间独立的关系,以及这种关联与支架置入到NCS之间时间的关系。该研究在2011年至2006年之间进行,共纳入了梅奥诊所(明尼苏达州罗彻斯特市)24,313例N

支架内再狭窄病变(图)

支架内再狭窄病变

NEJM:无症状性颈动脉狭窄:支架不劣于动脉内膜切除术

先前的临床试验表明,以捕捉和栓子清除装置进行颈动脉支架置入术(“栓塞保护”)是平均或高风险手术并发症患者的一种有效的替代颈动脉内膜切除术的方法。原始出处:Kenneth Rosenfield,Jon S. Matsumura,Seemant Chaturvedi,Randomized Trial of Stent versus Surgery for Asymptomatic Carotid St

NEJM:支架VS动脉内膜切除术治疗颈动脉狭窄的10年研究结果

在颈动脉血管内膜切除术vs支架的试验中,考虑到围手术期卒中,心肌梗死或死亡的主要复合终点,或任何之后4年的随访中发生同侧卒中的风险时,我们发现支架组与手术组之间没有显著差异。因此将随访时间延长到了10年。

JAMA Surg:为何接受冠脉支架介入术与患者预后明显相关?

背景目前医生主要依据患者疾病原因推迟冠状动脉支架置入术。然而,防止支架的原因或许是导致民众出现术后主要不良心血管事件(MACE)的一个重要的风险因素。 目的该研究的目的是确定冠状动脉支架放置术指征是否为导致民众出现MACE的主要危险因素。 设计该研究为回顾性队列研究,参与人员均于2000.1.1-2010.12.31在美国退伍军人医院接受冠状动脉支架置入术,并在2年内接受非心脏手术。研究人员使用逻

Baidu
map
Baidu
map
Baidu
map